title: Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab.
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto. Rua D. Manuel II, s/n, ex-CICAP, 4099-001 Porto, Portugal.
authors.forename: Susana
authors.initials: S
authors.lastname: Vilaça
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto. Rua D. Manuel II, s/n, ex-CICAP, 4099-001 Porto, Portugal, Medical School, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal.
authors.forename: Tiago
authors.initials: T
authors.lastname: Torres
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto. Rua D. Manuel II, s/n, ex-CICAP, 4099-001 Porto, Portugal, Medical School, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal.
authors.forename: Manuela
authors.initials: M
authors.lastname: Selores
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D057915:Drug Substitution; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D058566:Sacroiliitis / Q000139:chemically induced*; D000069549:Ustekinumab
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069549:Ustekinumab; D000068800:Etanercept